Affinity Asset Advisors’s Apogee Therapeutics APGE Stock Holding History
Bought
Maintained
Sold
Other funds holding APGE
Affinity Asset Advisors's APGE Position: Q3 2026 in Review
Affinity Asset Advisors sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 987,000 shares — an estimated $131M sold.
Affinity Asset Advisors first reported a position in APGE in Q3 2023 and held it in 12 quarters. The position peaked at $131M in Q2 2026. 2 funds tracked by Wall St. Rank hold APGE as of Q3 2026.
- Affinity Asset Advisors reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
- Affinity Asset Advisors sold 987,000 Apogee Therapeutics shares in Q3 2026, an estimated $131M.
- Affinity Asset Advisors first reported a position in Apogee Therapeutics in Q3 2023 and held it in 12 quarters.
- Affinity Asset Advisors's Apogee Therapeutics position peaked at $131M in Q2 2026.
- 2 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.
Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.